# Comparative Study of Aryl *O*-, *C*-, and *S*-Mannopyranosides as Potential Adhesion Inhibitors Toward Uropathogenic *E*. *coli* FimH

Leila Mousavifar,<sup>a,\*</sup> Gérard Vergoten,<sup>c</sup> Guillaume Charron,<sup>a</sup> and René Roy<sup>a,b,d\*</sup>

<sup>a</sup> Department of Chemistry, Université du Québec à Montréal, P.O. Box 8888, Succ. Centre-Ville, Montréal, Québec H3C 3P8, Canada. <u>roy.rene@ugam.ca</u>

<sup>b</sup> INRS-Institut Armand-Frappier, Université du Québec, 531 boul. des Prairies, Laval, Québec, H7V 1B7, Canada.

<sup>c</sup> Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), UMR8576 du CNRS, Université de Lille, F-59000 Lille, France;

<sup>d</sup> Glycovax Pharma Inc., 424 Guy, Suite 202, Montreal, Quebec, Canada, H3J 1S6

#### Supplementary

## Contents

G	eneral Experimental:	S2
1	Synthesis of 6-Aminohexyl α–D-mannopyranoside (4)	S4
	Scheme 1 Synthesis of 6-Aminohexyl $\alpha$ –D-mannopyranoside (4) <sup>1–3</sup>	S4
	Figure S.1. <sup>1</sup> H NMR spectrum of compound S2 (CDCl <sub>3</sub> , 300 MHz)	S5
	Figure S.2 <sup>13</sup> C NMR spectrum of compound S2 (CDCl <sub>3</sub> , 75 MHz)	S6
	Figure S.3. <sup>1</sup> H NMR spectrum of compound S3 (CDCl <sub>3</sub> , 300 MHz)	S6
	Figure S.4. FTIR spectrum of compound S3	S6
	Figure S.5. <sup>13</sup> C NMR spectrum of compound S3 (CDCl <sub>3</sub> , 75MHz)	S6
	Figure S.6. <sup>1</sup> H NMR spectrum of compound 4 (CD <sub>3</sub> OD, 300 MHz)	S7
	Figure S.7. <sup>1</sup> HNMR spectrum of compound 4 (CD <sub>3</sub> OD, 300 MHz)	S8
	Figure S.8. <sup>13</sup> C NMR spectrum of compound 4 (CD <sub>3</sub> OD, 75 MHz)	S8
2	Allyl 2,3,4,6-tetra-O-acetyl-1-thio-α-D-mannopyranoside 9.	S8
	Figure S.9. <sup>1</sup> H NMR spectrum of compound 9 (CDCl <sub>3</sub> , 300 MHz)	S8
	Figure S10. <sup>13</sup> C NMR spectrum of compound 9 (CDCl <sub>3</sub> , 75 MHz)	S9
	Figure S.11. COSY of compound 9 (CDCl <sub>3</sub> , 300 MHz)	S9
	Figure S.12. HSQC of compound 9 (CDCl <sub>3</sub> , 300 MHz)	. <b>S</b> 10
	Figure S.13. ESI <sup>+</sup> HRMS spectrum of compound 9	. <b>S</b> 10
3	(2E)-3-(1,1'-biphenyl-2-propen-1-yl) 2,3,4,6-tetra-O-acetyl-1-thio-α-D-mannopyranoside 11	. S10
	Figure S.14. <sup>1</sup> H NMR spectrum of compound 11 (CDCl <sub>3</sub> , 300 MHz)	. S10

Figure S.15. <sup>13</sup> C NMR spectrum of compound 11 (CDCl <sub>3</sub> , 75 MHz)	11
Figure S.16. ESI <sup>+</sup> HRMS spectrum of compound 11	11
4 (2 <i>E</i> )-3-(1,1'-biphenyl-2-propen-1-yl) 1-thio- $\alpha$ -D-mannopyranoside 12	11
Figure S.17. <sup>1</sup> H NMR spectrum of compound 12 (CD <sub>3</sub> OD, 600 MHz)	11
Figure S.18. <sup>13</sup> C NMR spectrum of compound 12 (CD <sub>3</sub> OD, 151 MHz)	12
Figure S.19. HPLC-TOF-MAS analysis of fractions of compound 12	12
5 Crystal Data and Structure Refinements	13
Figure S.20. ORTEP diagram for the D mannoside 5.CCDC no: 1840503	13
Thermal ellipsoids are drawn at the 50% probability level	13
$(2E)$ -3- $(1, 1'-biphenyl-2-propen-1-yl) \alpha$ -D-mannopyranoside $(5)$	14
Figure S.21.ORTEP diagram for the X-Ray structure of <i>C</i> -linked mannoside 6.CCDC no: 1871374. Thermal ellipsoids are drawn at the 50% probability level	15
9-2. (E)-4-[3-(α-D-Mannopyranosyl)prop-1-en-1-yl]-1,1'-biphenyl (6)	16
Figure S.22. Representation of two <i>O</i> -linked $\alpha$ –D-mannopyranosides having common 1,1'-biphenyl aglycones; the mannoside residue of compound 5 was superimpose with that of mannoside 7 in the crystalline structure of the protein (PDB 4AV5). <sup>6</sup>	17
Figure S.18 Sensorgram of kinetic analysis of FimH:6-aminohexyl α-D-mannopyranoside affinity S1 by SPR.	17

- 1 S. Tao, T. W. Jia, Y. Yang and L. Q. Chu, ACS Sensors., 2017, 2, 57–60.
- 2 V. Dhaware, M. Kar, S. Hotha and S. Sen Gupta, *Langmuir*, 2013, **29**, 5659–5667.
- 3 K. Öberg, J. Ropponen, J. Kelly, P. Löwenhielm, M. Berglin and M. Malkoch, *Langmuir*, 2013, **29**, 456–465.
- 4 O. V Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, *J. Appl. Cryst.*, 2009, **42**, 339–341.
- 5 G. M. Sheldrick, *Acta Crystallogr. Sect. A*, 2015, **71**, 3–8.
- 6 A. Wellens, M. Lahmann, M. Touaibia, J. Vaucher, S. Oscarson, R. Roy, H. Remaut and J. Bouckaert, *Biochemistry*, 2012, **51**, 4790–4799.

# **General Experimental:**

Reactions were carried out under Nitrogen using commercially available ACS grade solvents which were stored over 4 Å molecular sieves. Solutions in organic solvents were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. Reagents were obtained from Sigma

Aldrich. Reactions were monitored by thin-layer chromatography using silica gel 60 F254 coated plates (E. Merck). NMR spectra were recorded on Varian Inova AS600 and Bruker Avance III HD 600 MHz spectrometer. Proton and carbon chemical shifts ( $\delta$ ) are reported in ppm relative to the chemical shift of residual CHCl<sub>3</sub>, which was set at 7.28 ppm (<sup>1</sup>H) and 77.16 ppm (<sup>13</sup>C{H}). Coupling constants (J) are reported in Hertz (Hz) and the following abbreviations are used for peak multiplicities: singlet (s), doublet (d), doublet of doublets (dd), doublet of doublet with equal coupling constants (t<sub>ap</sub>), triplet (t), multiplet (m). Assignments were made using COSY (Correlated SpectroscopY) and HSQC (Heteronuclear Single Quantum Coherence) experiments. High-resolution mass spectra (HRMS) were measured with a LC-MS-TOF (Liquid Chromatography Mass Spectrometry Time of Flight) instrument (Agilent Technologies) in positive electrospray mode by the analytical platform of UQAM. SPR were performed with a Biacore T200 on a CM5 sensor chip (GE Healthcare Life Sciences). Optical rotations were measured with a JASCO P-1010 polarimeter. Melting points were measured on a Fisher Jones apparatus.

#### A. General procedure for de-*O*-acetylation.

The acetylated mannosides **S4 and 11** were dissolved in dry MeOH (3 mL), a solution of sodium methoxide (1 M in MeOH, 0.5 equiv) was added and the reaction mixture was stirred at room temperature until disappearance of the starting material. The solution was neutralized by addition of ion-exchange resin (Amberlite IR 120), filtered, washed with MeOH and then the solvent was removed in vacuum compounds **4** and **12**. Lyophilization of **4** yielded the fully deprotected mannoside desired compound. Compound **12** was purified by reversed phase high performance liquid chromatography (RP-HPLC) (A:  $H_2O + 0.1\%$  trifluoroacetic acid, B: ACN + 0.1% trifluoroacetic acid, 5 mL/min).

1. Synthesis of 6-Aminohexyl α–D-mannopyranoside (4)



Scheme 1 Synthesis of 6-Aminohexyl α–D-mannopyranoside (4)<sup>1–3</sup>

#### 6-Chlorohexyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (S2)

Penta-*O*-acetyl-mannopyranose (**8**) (507 mg, 1.30 mmol, 1.0 eq.) and 6-chlorohexanol (340 µL, 2.56 mmol, 2. 0 eq.) were dissolved in dry DCM (10 mL) at 0 °C. Et<sub>2</sub>O.BF<sub>3</sub> (480 µL, 3.90 mmol, 3.0 eq.) was added dropwise. The mixture was stirred at 0 °C for 1 h and then at 40 °C for 17 h. The solution was neutralized by adding a saturated solution of NaHCO<sub>3</sub> (10 mL). The organic phase was separated, washed with water and dried over sodium sulfate. The DCM was removed under vacuum. The crude residue was purified by silica gel column chromatography (Petroleum ether: EtOAc, 3:2) to afford the pure title compound as a yellow oil (404 mg, 0.895 mmol) in 66 % yield;  $R_f$  = 0.62 (Petroleum ether: EtOAc, 3:2). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  5.36 (dd, 1H,  $J_{2,3}$ = 3 Hz,  $J_{3,4}$  = 9 Hz, H-3), 5.26- 5.21 (m, 2H, H-4, H-2), 4.79 (d, 1H,  $J_{1,2}$ = 1.5 Hz, H-1), 4.27 (dd, 1H,  $J_{6a, 6b}$  = 12.2 Hz,  $J_{5, 6a}$  = 5.3 Hz, H-6a), 4.09 (dd, 1H,  $J_{6a, 6b}$  = 12.2 Hz,  $J_{5, 6b}$  = 2.3 Hz, H-6b), 3.95 (ddd, 1H,  $J_{4, 5}$  = 8.9 Hz,  $J_{5, 6a}$  = 5.4 Hz,  $J_{5, 6b}$  = 2.4 Hz, H-5), 3.72-3.64 (m, 1H. OCHH), 3.53 (t, 1H,  $J_{H-H}$  = 6Hz, -CH<sub>2</sub>Cl), 3.44 (m, 1H, OCHH), 2.14 (s, 3H, OAc), 2.09 (s, 3H, OAc), 2.03 (s, 3H, OAc), 1.98 (s, 3H, OAc), 1.80-1.73 (m, 2H), 1.72 - 1.59 (m, 2H), 1.42 - 1.40 (m, 4H). <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>):  $\delta$  170.6-169.7 (4C=O), 97.6; 69.7; 69.1; 68.4 (CH<sub>2</sub>-O); 68.3, 66.3, 62.5; 45.0, 32.4 (CH<sub>2</sub>), 29.1 (CH<sub>2</sub>), 26.6 (CH<sub>2</sub>), 25.4 (CH<sub>2</sub>), 20.9-20.7 (4 OCOCH<sub>3</sub>). Other physical data matched those of the literature.<sup>2</sup>

#### 6-Azidohexyl 2, 3, 4, 6-tetra-O-acetyl-α-D-mannopyranoside (S3).

The above 6-chlorohexyl derivative S2 (551 mg, 1.18 mmol, 1.0 eq.) was dissolved in dry DMF (5 mL). Sodium azide (385 mg, 5.92 mmol, 5.0 eq.) and sodium iodide (40 mg, 0.22 eq.) were added to the mixture. The solution was stirred at 80 °C for 24 h and then at room temperature for 16 h. The mixture was diluted with water and the aqueous phase was extracted 3 times with EtOAc. The organic phase was washed with water, dried and concentrated under reduced pressure. The product was purified by silica gel column chromatography (Toluene, EtOAc, 3:2) to yield pure title compound as a yellow oil (521 mg, 1.10 mmol, 93 %);  $R_f = 0.67$  (Toluene, EtOAc, 3:2). 521 mg, 1.10 mmol, IR: (2104 cm<sup>-1</sup> for N<sub>3</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  5.36 (dd, 1H,  $J_{2,3}$ = 3.3 Hz,  $J_{3,4}$ = 10 Hz, H-3), 5.32-5.22 (m, 2H, H-4, H-2), 4.81(d, 1H,  $J_{1,2}$ = 1.6 Hz, H-1), 4.29 (dd, 1H,  $J_{6a, 6b}$ = 12.2 Hz  $J_{5, 6a}$  = 5.3 Hz, H-6a), 4.09 (dd, 1H,  $J_{6a, 6b}$  = 12.2 Hz,  $J_{5, 6b}$  = 2.4 Hz, H-6b), 3.98 (ddd, 1H,  $J_{4, 5}$  = 9.4 Hz,  $J_{5, 6a}$  = 5.3 Hz,  $J_{5, 6b}$  = 2.4 Hz, H-5), 3.76-3.66 (m, 1H. OCHH), 3.49-3.42 (m, 1H, OCHH), 3.29 (t, 1H,  $J_{H-H}$  = 6.8 Hz, -CH<sub>2</sub>-N<sub>3</sub>), 2.15 - 1,99 (s, 12H, OAc. 1.73 - 1.50 (m, 4H), 1.50 - 1.29 (m, 4H). <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>): 170.6 - 169.7 (4×CO), 97.6 (CH<sub>1</sub>), 69.7; 69,1, 68.4, 68.3, 66.3, 62.5, 51.3 (CH<sub>2</sub>-N<sub>3</sub>), 29.1 (CH<sub>2</sub>), 28.7 (CH<sub>2</sub>), 26.5 (CH<sub>2</sub>), 25.7 (CH<sub>2</sub>), 20. 9- 20.7 (4× OCOCH<sub>3</sub>).<sup>2</sup>



Figure S.1. <sup>1</sup>H NMR spectrum of compound S2 (CDCl<sub>3</sub>, 300 MHz)





Figure S.2 <sup>13</sup>C NMR spectrum of compound S2 (CDCl<sub>3</sub>, 75 MHz)

Figure S.3. <sup>1</sup>H NMR spectrum of compound S3 (CDCl<sub>3</sub>, 300 MHz)





Figure S.5. <sup>13</sup> C NMR spectrum of compound S3 (CDCl<sub>3</sub>, 75MHz)

6-Azidohexyl α-D-mannopyranoside (4).

This compound was prepared according to the published procedure.<sup>3</sup> <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$ : 4.75 (d, 1H), 3.82-3.63 (m, 8H), 3. 31 (t, *J* = 6.9 Hz, 2H), 1.69 – 1.48 (m, 4H), 1.45 – 1.29 (m, 4H). Other physical data matched those of the literature.



Figure S.6.<sup>1</sup> H NMR spectrum of compound 4 (CD<sub>3</sub>OD, 300 MHz)

# 6-Aminohexyl α-D-mannopyranoside (4).

This compound was prepared according to the published procedure.<sup>3 1</sup>H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$ : 4.72 (d, 1H), 3.92-3.81 (m, 2H), 3.79-3.65 (m, 3H), 3.65-3.56 (m, 2H), 3.56 – 3.47 (m, 1H), 2.62 (t, *J* = 7.9 Hz, 2H), 1.61-1.37 (m, 10H). <sup>13</sup>C{<sup>1</sup>H} NMR (CD<sub>3</sub>OD):  $\delta$  100.15, 73.2, 71.2, 70.8, 67.2, 67.0, 61.5, 40.8, 31.4, 29.0, 29.0, 26.2, 25.7.





Figure S.7. <sup>1</sup>HNMR spectrum of compound 4 (CD<sub>3</sub>OD, 300 MHz)

Figure S.8. <sup>13</sup> C NMR spectrum of compound 4 (CD<sub>3</sub>OD, 75 MHz)

# 2 Allyl 2,3,4,6-tetra-O-acetyl-1-thio-α-D-mannopyranoside 9.



Figure S.9. <sup>1</sup>H NMR spectrum of compound 9 (CDCl<sub>3</sub>, 300 MHz)



Figure S10. <sup>13</sup>C NMR spectrum of compound 9 (CDCl<sub>3</sub>, 75 MHz)



Figure S.11. COSY of compound 9 (CDCl<sub>3</sub>, 300 MHz)





Figure S.12. HSQC of compound 9 (CDCl<sub>3</sub>, 300 MHz)

Figure S.13. ESI<sup>+</sup>HRMS spectrum of compound 9

# 3 (2E)-3-(1,1'-biphenyl-2-propen-1-yl) 2,3,4,6-tetra-O-acetyl-1-thio–α-D-mannopyranoside 11



Figure S.14. <sup>1</sup>H NMR spectrum of compound 11 (CDCl<sub>3</sub>, 300 MHz)



Figure S.16. ESI<sup>+</sup>HRMS spectrum of compound 11

# 4 (2E)-3-(1,1'-biphenyl-2-propen-1-yl) 1-thio- $\alpha$ -D-mannopyranoside 12.

This compound was deprotected according to general procedure **B**.



Figure S.17. <sup>1</sup>H NMR spectrum of compound 12 (CD<sub>3</sub>OD, 600 MHz)



Figure S.18. <sup>13</sup>C NMR spectrum of compound 12 (CD<sub>3</sub>OD, 151 MHz)



Figure S.19. HPLC-TOF-MAS analysis of fractions of compound 12

## 5 Crystal Data and Structure Refinements

## (2*E*)-3-(1, 1'-biphenyl-2-propen-1-yl) α-D-mannopyranoside

Single crystals of  $C_{21}H_{24}O_6$  were crystallized from DCM/MeOH. A suitable crystal was selected and mounted on a cryoloop on a Bruker Venture Metal jet diffractometer. The crystal was kept at 150 K during data collection. Using Olex2<sup>4</sup>, the structure was solved with the XT<sup>5</sup> structure solution program using Intrinsic Phasing and refined with the XL<sup>5</sup> refinement package using Least Squares minimization.

**Crystal Data** for C<sub>21</sub>H<sub>24</sub>O<sub>6</sub> (*M* =372.40 g/mol): orthorhombic, space group P2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> (no. 19), *a* = 6.2463(3) Å, *b* = 7.5145(3) Å, *c* = 39.1736(18) Å, *V* = 1838.72(14) Å<sup>3</sup>, *Z* = 4, *T* = 150 K,  $\mu$ (GaK $\alpha$ ) = 0.520 mm<sup>-1</sup>, *Dcalc* = 1.345 g/cm<sup>3</sup>, 22152 reflections measured (3.924° ≤ 2 $\Theta$  ≤ 107.97°), 3372 unique (*R*<sub>int</sub> = 0.0551, R<sub>sigma</sub> = 0.0354) which were used in all calculations. The final *R*<sub>1</sub> was 0.0494 (I > 2 $\sigma$ (I)) and *wR*<sub>2</sub> was 0.1208 (all data).

Crystallographic data for the structure reported in this paper has been deposited at the Cambridge Crystallographic Data Centre (CCDC) with deposition no: 1840503 for  $C_{21}H_{24}O_6$ . Supplementary data can be obtained free of charge from CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: (+44)1223-336-033; e-mail: deposit@ccdc.cam.ac.uk



Figure S.20. ORTEP diagram for the D mannoside 5.CCDC no: 1840503 Thermal ellipsoids are drawn at the 50% probability level.

#### Bond precision: C-C = 0.0056 A Wavelength=1.34139 Cell: b=7.5145(3) c=39.1736(18) a=6.2463(3) alpha=90 beta=90 gamma=90 150 K Temperature: Calculated Reported 1838.72(14) 1838.72(14) Volume P 21 21 21 P 21 21 21 Space group Hall group P 2ac 2ab P 2ac 2ab Moiety formula C21 H24 O6 C21 H24 O6 Sum formula C21 H24 O6 C21 H24 O6 372.40 372.40 Mr 1.345 1.345 Dx, g cm-3 Z 4 4 Mu (mm-1) 0.516 0.520 F000 792.0 792.0 F000' 794.00 h,k,lmax 7,9,47 7,9,47 Nref 3376[ 2007] 3372 Tmin, Tmax 0.954,0.985 0.489,0.751 Tmin' 0.834 Correction method= # Reported T Limits: Tmin=0.489 Tmax=0.751 AbsCorr = MULTI-SCAN Data completeness= 1.68/1.00 Theta(max) = 53.985R(reflections) = 0.0494( 2868) wR2(reflections) = 0.1228( 3372) S = 1.048Npar= 261

#### (2*E*)-3-(1, 1'-biphenyl-2-propen-1-yl) α-D-mannopyranoside(5)

The following ALERTS were generated. Each ALERT has the format test-name ALERT alert-type alert-level. Click on the hyperlinks for more details of the test.

#### (E)-4-[3-(α-D-Mannopyranosyl)prop-1-en-1-yl]-1,1'-biphenyl (6).

Single crystals of  $C_{21}H_{24}O_5$  were crystallized from MeOH. A suitable crystal was selected and mounted on a cryoloop on a Bruker Venture Metaljet diffractometer. The crystal was kept at 150 K during data collection. Using Olex2<sup>4</sup>, the structure was solved with the XT<sup>5</sup> structure solution program using Intrinsic Phasing and refined with the XL<sup>5</sup> refinement package using Least Squares minimization.

**Crystal Data** for C<sub>21</sub>H<sub>24</sub>O<sub>5</sub> (M =356.40 g/mol): monoclinic, space group P21 (no. 4), a = 9.7448(4) Å, b = 8.1887(4) Å, c = 21.6060(9) Å,  $\beta$  = 92.097(2)°, V = 1722.94(13) Å3, Z = 4, T = 150 K,  $\mu$ (GaK $\alpha$ ) = 0.506

mm-1, Dcalc = 1.374 g/cm3, 46514 reflections measured ( $3.56^\circ \le 20 \le 121.384^\circ$ ), 7923 unique (Rint = 0.0693, R sigma = 0.0486) which were used in all calculations. The final R1 was 0.0518 (I >  $2\sigma$ (I)) and wR2 was 0.1405.

Crystallographic data for the structure reported in this paper has been deposited at the Cambridge Crystallographic Data Centre (CCDC) with deposition no: 1871374 for C21H24O5. Supplementary data can be obtained free of charge from CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: (+44)1223-336-033; e-mail: <u>deposit@ccdc.cam.ac.uk</u>



Figure S.21.ORTEP diagram for the X-Ray structure of *C*-linked mannoside 6.CCDC no: 1871374. Thermal ellipsoids are drawn at the 50% probability level.

Bond precision:	C-C = 0.0053 A	Wavelength=1.34139		
Cell:	a=9.7448(4)	b=8.1887(4)	c=21.6060(9)	
	alpha=90	beta=92.097(2)	gamma=90	
Temperature:	150 K			
	Calculated	Repo	rted	
Volume	1722.95(13)	1722	.94(13)	
Space group	P 21	P 1 21 1		
Hall group	P 2yb	P 2y	b	
Moiety formula	C21 H24 O5	C21	H24 O5	
Sum formula	C21 H24 O5	C21	H24 O5	
Mr	356.40	356.40		
Dx,g cm-3	1.374	1.374		
Z	4	4		
Mu (mm-1)	0.506	0.506		
F000	760.0	760.0		
F000'	761.85			
h,k,lmax	12,10,28	12,1	0,28	
Nref	7934[ 4247]	7923		
Tmin, Tmax	0.947,0.955	0.416,0.516		
Tmin'	0.936			
Correction metho AbsCorr = MULTI	od= # Reported T -SCAN	Limits: Tmin=0	.416 Tmax=0.516	
Data completene:	ss= 1.87/1.00	Theta (max) =	60.692	
R(reflections) =	0.0518( 6500)	wR2(reflecti	ons)= 0.1405( 7923)	
S = 0.913	Npar=	503		

The following ALERTS were generated. Each ALERT has the format test-name\_ALERT\_alert-type\_alert-level. Click on the hyperlinks for more details of the test.



Figure S.22. Representation of two *O*-linked α–D-mannopyranosides having common 1,1'-biphenyl aglycones; the mannoside residue of compound 5 was superimpose with that of mannoside 7 in the crystalline structure of the protein (PDB 4AV5).<sup>6</sup>



Residuals:

Fitted constants:

ka (1/Ms)	Kd (1/s)	KD (M)	Rmax (RU)	tc	Chi <sup>2</sup> (RU <sup>2</sup> )	U-value
5343	2,06E-04	3,86E-08	7129	5,75E+06	783	1

Figure S.23. Sensorgram of kinetic analysis of FimH:6-aminohexyl α-D-mannopyranoside affinity by SPR.